David Dai
Stock Analyst at UBS
(0.30)
# 4,033
Out of 4,786 analysts
20
Total ratings
16.67%
Success rate
-28.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Upgrades: Buy | $100 | $70.92 | +41.00% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $6.60 | +112.12% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $29.67 | -19.11% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $88.51 | -0.58% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $2.13 | +838.97% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $11.88 | +194.61% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $42.09 | +71.06% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $27.00 | +155.56% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $16.38 | +205.25% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $3.33 | +410.51% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $7.57 | +296.30% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $24.49 | +145.00% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $12.29 | +201.18% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.76 | +3,608.61% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $13.99 | +185.92% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.27 | +3,049.61% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.84 | +2,617.39% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $41.12 | +26.46% | 1 | Mar 17, 2020 |
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $70.92
Upside: +41.00%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $6.60
Upside: +112.12%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $29.67
Upside: -19.11%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $88.51
Upside: -0.58%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.13
Upside: +838.97%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $11.88
Upside: +194.61%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $42.09
Upside: +71.06%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $27.00
Upside: +155.56%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $16.38
Upside: +205.25%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $3.33
Upside: +410.51%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $7.57
Upside: +296.30%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $24.49
Upside: +145.00%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $12.29
Upside: +201.18%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.76
Upside: +3,608.61%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $13.99
Upside: +185.92%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.27
Upside: +3,049.61%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.84
Upside: +2,617.39%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $41.12
Upside: +26.46%